



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/581,911	06/07/2006	Naoko Kida	Q95279	8940
23373 7590 10/13/2009 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037			EXAMINER UNDERDAHL, THANE E	
			ART UNIT 1651	PAPER NUMBER
			MAIL DATE 10/13/2009	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

### Office Action Summary

**Application No.**

10/581,911

**Applicant(s)**

KIDA ET AL.

**Examiner**

THANE UNDERDAHL

**Art Unit**

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 24 July 2009.  
2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.  
3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-3,5-7 and 9-11 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.  
6) ☒ Claim(s) 1-3,5-7 and 9-11 is/are rejected.  
7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.  
8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.  
10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)  
2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  
3) ☒ Information Disclosure Statement(s) (PTO-85/86)  
Paper No(s)/Mail Date 4/13/09 and 6/25/09  
4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_  
5) ☐ Notice of Inventor's Patent Application  
6) ☐ Other: \_\_\_\_\_

**Detailed Action**

***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/24/09 has been entered.

This Office Action is in response to the Applicant's reply received 7/24/09. Claims 1-3, 5-7, 9-11 are pending. No Claims are withdrawn. Claims 4 and 8 are cancelled. No Claims have been amended since 7/28/08. No Claims are new. Claims 1-3, 5-7, 9-11 are considered in this Office Action.

**Response to Applicant's Arguments**

In the response submitted by the Applicant the 35 U.S.C § 103 (a) rejection of claims 1-3, 5, 6, 9-11 based on Goodwin #1, Goodwin #2, Goodwin #3, and Schwarz et al. in light of support from Unsworth et al., Wikipedia, Bock et al. and Bartlett were considered but not found persuasive.

The Applicant arguments are drawn to mesenchymal stem cells (Applicant's Response, pg 3, 4 and 5). These arguments are not commensurate with the scope of the claims since "mesenchymal stem cells" are not limited in the claims only "bone marrow mesenchymal cells". "Mesenchymal stem cells" is a far broader limitation thane

"bone marrow mesenchymal cells" since "mesenchymal stem cells" can be obtained from embryos as well as dental pulp. Furthermore the Applicant asserts that the previous Final Office Action (11/24/08) states that "Goodwin #1 discloses promoting differentiation of mesenchymal stem cells to form cartilage tissue" on page 4 (Applicant's response, pg 5 b). However nowhere in the previous office actions did the Examiner use the phrase "mesenchymal stem cell", page 4 or otherwise.

The Applicant's argument that the inventive step is culturing the mesenchymal stem cells to confluence in 2D, prior to subculturing in 3D is an inventive step and was not known or expected in the art is not persuasive. The Examiner did consider the references of Majumdar et al., Metzger et al., White et al. and Alhadlaq et al., however these references do not explicitly discourage the culturing of mesenchymal stem cells to confluence. Indeed to progress prosecution the Examiner found 2 additional articles that bone marrow stromal cells (a.k.a. bone marrow mesenchymal cells as taught by previously cited wiki). Furthermore there are examples in the art such as in Kadner et al. that teach that mesenchymal stem cells are cultured to confluence (Kadner, pg 1057, col 1, sec 3.1). There are also examples in the art such as Banfi et al. teach that mesenchymal stem cells are cultured to a range of confluence greater than 90% (Banfi, pg 708, col 2 last paragraph) to confluence (Banfi, pg 703, col 2, 1st and 2nd full paragraphs). Even the most recent art found to the Applicants U.S priority date shows that mesenchymal stem cells are cultured to confluence (Ito, online Feb 3, 2004). Therefore it is not unique in the art to cultured MSCs to confluence or a range of confluency.

The Applicant also argues that newly amended claim 1 teaches that claim 1 step (b) limits that the subculturing the confluent 2-D cells to a 3-D culture is a single element and that none of the references teaches this limitation. Respectfully this is not the case. The open language of comprising, it is obvious to add steps since this is not excluded by the claims. This is supported by M.P.E.P. § 2111.03 which states "The transition 'comprising' in a method claim indicates that the claim is open-ended and allows for additional steps." Therefore the step of subculturing the cells from the confluent 2-D culture to 3-D culture does not exclude that other steps such as re-seeding the 2-D culture on a 3-D scaffold. Furthermore claim 1 step (b) is quite broad and as interpreted by the Examiner is not limited to a single element. The active step of "subculturing" is broad and reads on all the all the common steps one of ordinary skill in the art would typically take during culturing such as seeding cells, trypsin digestion, passing cells, changing media ect. In short claim 1 step (b) by using the active term "subculturing" does not limit the method to a single element.

The Applicant argues that the current method is unexpectedly superior because it does not require a carrier. However, unexpected results can only be considered by the Examiner if they are commensurate in scope with the claims (M.P.E.P. § 716.02). Indeed if this is the inventive step then such an important exclusion should be reflected in the claims. The current claims do not contain such a limitation therefore such arguments are giving little patentable weight at this time. Furthermore the Applicant appears to imply that since the specification discloses that a carrier is not necessary that the invention is novel. However, according to M.P.E.P. § 2111, the

pending claims must be given their broadest reasonable interpretation consistent with the specification. Broad interpretation by the examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than is justified. In *In re Prater* (citations omitted), the court ruled that "reading a claim in light of the specification, to thereby interpret limitations explicitly recited in the claim, is a quite different thing from reading limitations of the specification into a claim,' to thereby narrow the scope of the claim by implicitly adding disclosed limitations which have no express basis in the claim. The court found that applicant was advocating the latter, i.e., the impermissible importation of subject matter from the specification into the claim.

Therefore the rejection stands and is repeated below.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-3, 5, 6, 9-11 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Goodwin #1 (U.S. Patent # 5,496,722), Goodwin #2 (In Vitro. Cell Dev. Biol, vol 33, page 358, 1997), Goodwin #3 (In Vitro. Cell Dev. Biol, vol 33, page 366, 1997) and Schwarz et al. (U.S. Patent # 5026650) in light of support from Unsworth et al. (Nature Medicine, 1998) Wikipedia (Definition—Bone Marrow), Bock et

al. (Tissue Engineering of Cartilage and Bone) and Bartlett (Ovarian Cancer Methods and Protocols).

These claims are to a method of making cartilage tissue comprising the following steps:

- 2-D culturing of bone marrow mesenchymal cells to confluence
- Subculturing the cells 3-D in a microgravity environment using a uniaxial rotary bioreactor that provides a simulated microgravity environment on earth via controlling the rotational speed of the bioreactor.
- Obtaining tissue expressing Type II collagen.

The claims further limit that the rotary bioreactor provides a gravity that is 1/10 to 1/100 of the ground gravity for an object for a time average basis and is the result of controlled rotation speed. The rotary bioreactor is a **Rotating Wall Vessel (RWV)** bioreactor. The cells are seeded in the bioreactor at a density of  $10^6$  to  $10^7$  cells/cm<sup>3</sup> at a rotational speed of 8.5 to 25 rpm in a 5 cm diameter RWV. This rotational speed is adjusted to minimize the influence of the ground gravity of the cells. The claims further limit that the bone marrow mesenchymal cells are isolated from a subject in need of a cartilage tissue transplant. The resulting cartilage tissue has a major axis of 1 cm or more.

Goodwin #1 teaches that a mixture of chondrocytes and stromal cells are obtained from bone marrow of mammalian femurs (Goodwin #1, col 12 lines 50-60 and col 13 lines 40-50). One of ordinary skill in the art would recognize that bone marrow mesenchymal cells are also called bone marrow stromal cells (as supported by Wikipedia-Bone Marrow). Therefore one of ordinary skill in the art would recognize that

the cells obtained by Goodwin #1 comprise bone marrow mesenchymal cells. These cells are transferred to a fluid culture medium and suspended in culture medium at a density of  $1 \times 10^6$  cells/ml and seeded on a culture matrix. This seeded culture matrix was then placed in a RWV, preferably one taught by the incorporated reference of Schwarz et al. (Goodwin col 8, lines 5-10) that can simulate an environment of  $10^{-2}$  of ground gravity as supported by Unsworth et al. (Unsworth et al., page 902, col 1).

Goodwin #1 teach that culturing the mixture of bone marrow mesenchymal cells and chondrocytes produced cartilaginous tissue structures that contained Type II collagen (Goodwin #1, col 13, lines 14-19). Goodwin #1 teach that the cells were cultured up to 65 days and after 1000 hours (~42 days) produced a tissue mass at least 0.4 cm in length (Goodwin #1, col 13, lines 10-20).

The RWV of Schwarz et al. can have a controlled rotation between 5 and 40 RPM (Schwarz, col 7, lines 5-10). Schwarz et al. teach that the rotation speed is increased and decreased to synchronize the falling cells with the rotating reactor so the cells are maintained floating in suspension (i.e. defy gravity) (Schwarz, Claim 3). Goodwin #1 also teach that the rotational speed of the RWV is adjusted to keep the cells in suspension and prevent collision of cells (Goodwin, col 8, lines 4-28).

What Goodwin #1 does not explicitly teach is that the bone marrow mesenchymal cells a first cultured to confluence then, subcultured in the RWV. One of ordinary skill in the art would recognize that expanding cells using traditional 2D culture flasks and then using those cells as an inoculum is a common practice in the art. This is supported by the teachings of Goodwin in two additional references (Goodwin #2 and



Goodwin #3). These two references by the same author teach that the other cells such as chondrocytes and ovarian tumor cells are initially cultured with traditional 2D techniques before being subculture in the RWV. Goodwin #2 teach that chondrocytes are isolated from the specimen and expanded in 2D cell cultures for two passages to produce sufficient numbers of cells to inoculation and subculture in a RWV (Goodwin #2, pg 359, col 1, Cell isolation). One of ordinary skill in the art would recognize that chondrocytes (cartilage cells) are cultured to confluence before passage as supported by Bock et al. (pg 107, 2nd paragraph). So it would have been obvious to someone skilled in the art to culture cartilage cells to confluence and then passing the cells to expand the culture to provide a sufficient number of cells before subculturing them in the RWV.

Furthermore Goodwin #3 teach that ovarian tumor cells are cultured in traditional 2D flasks for multiple passages before being trypsinized and inoculated into the RWV (Goodwin #3 page 367, Col 1 RWV cultures). One of ordinary skill in the art would recognize that ovarian cancer cells like chondrocytes are grown to confluence before passage as supported by Bartlett (page 163).

It would have been obvious to someone skilled in the art to use traditional 2D culture methods to expand the cells bone marrow mesenchymal cells and chondrocytes isolated from mammals by Goodwin #1 to grow the cells to confluence then inoculate them into the RWV for subculturing. Goodwin #2 and Goodwin #3 teach that this is common technique for isolated chondrocytes and for other cells such as ovarian tumor cells. This is a simple matter of applying known cell culture technique to expand and

produce enough cells for an adequate sized inoculum for an RWV. This would be an obvious improvement over simply isolating the necessary cells every time an inoculum for the RWV was necessary and would cut down on the time per experiment and mammals sacrificed. Therefore since using the known techniques of 2D cell culture would improve the overall RWV method of Goodwin #1 and were used for two other cell types by Goodwin #2 and #3 with success it would have been obvious to someone skilled in the art to use these known techniques to improve similar RWV methods (KSR International Co. v. Teleflex Inc., 550 U.S.--, 82 USPQ2d 1385 (2007)).

Neither of the references above teach the diameter of the RWV vessel or the concentrations of the cell concentrations needed to inoculate the RWV as limited in claim 6. However, one of ordinary skill in the art would recognize that limitations of vessel size and inoculum concentration are result effective variables. Absent any teaching of criticality by the applicant concerning these limitations, it would be *prima facie* obvious that one of ordinary skill in the art would recognize these limitations are result effective variables which can be met as a matter of routine optimization (M.P.E.P. § 2144.05 II).

Also while neither of the references above teach that cartilage tissue is formed of 1 cm or more this would have been obvious in view of the work of Goodwin #1. They teach that their bone marrow mesenchymal cells produce tissue masses of at least 0.4 cm in length after 1000 hours of culture and that these cells were cultured for up to 65 days. Since one of ordinary skill in the art would recognize that the size of the tissue is directly related to the length of time in the RWV culture, it would have been obvious to

someone skilled in the art that 1 cm long cartilage tissue could be formed given sufficient time. This is further supported by additional experimentation of Goodwin #1. They teach that other mesenchymal cells as well as epithelial cells were cultured for 45 days and did not reach a plateau phase and increased linearly as the culture progressed (Goodwin #1 col 9, lines 30-45).

Also claim 9 limits that the bone marrow mesenchymal cells are isolated from a subject in need of transplantation. The art is replete with references where bone marrow and cells are isolated from a subject. This is advantageous since these cells or their derivatives would be recognized as self by the subject and avoid inconvenient immunological side effects or even rejection of the cells if re-transplanted into the subject.

Therefore the references listed above renders obvious claims 1-3, 5, 6, 9-11.

Concerning the remaining 35 U.S.C § 103 (a) rejections in the Office Action the Applicant argues that since the amendments to claim 1 overcome the teachings of Goodwin #1, #2, #3 and Schwarz et al. in light of various supporting references over claims 1-3, 5, 6, 9-11 that they in turn overcome the remaining rejections that use these references. However as detailed above the Examiner disagrees and believes that the combination of Goodwin #1, #2, #3 and Schwarz et al. in light of supporting references is proper and in the absence of arguments to the contrary these rejections stand for the amended claims and are repeated below.

Claims 1-3, 5-7, and 9-11 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Goodwin #1, #2, #3 and Schwarz et al. in light of various supporting references as applied to claims 1-3, 5, 6, 9-11 above, and further in view of Yan et al. (U. S. Patent Application Publication # 2002/0168763) and Simpson et al. (U. S. Patent Application Publication # 2002/0090725). The description and rejection of claims 1-3, 5, 6, 9-11 are described in the 35 U.S.C § 102(a) rejection above. Claim 7 further limits the method of claim 1 by requiring TGF-  $\beta$  and/or dexamethasone in the culture medium.

While Goodwin #1 teach that "various growth factors" may be added to the culture medium to "emulate *in situ* conditions" (Goodwin #1, col 4, lines 3-5). While Goodwin #1 does not specifically teach TGF-  $\beta$  this would be obvious to one of ordinary skill in the art at the time the invention was made in view of Simpson et al. who teach the addition of TGF-  $\beta$  to the culture medium (Simpson et al., paragraph 98) to grow collagen matrices in a microgravity reactor (Simpson et al., paragraph 207) that contain cells from bone marrow (Simpson et al., paragraph 204). It would have been obvious to someone skilled in the art to modify the invention of Goodwin #1 with the teachings of Simpson et al. since both culture bone marrow cells in a microgravity reactor. The motivation comes from Goodwin #1 who desires to create a culture that emulates *in situ* conditions and one of ordinary skill in the art would recognize that TGF-  $\beta$  would be present in the body where bone marrow cells are cultured. The reasonable expectation of success is provided by Simpson et al. who teach the addition of TGF-  $\beta$  to the culture.

Likewise Goodwin #1 does not teach the addition of dexamethasone to their culture media, however this would be obvious at the time the invention was made in view of the teachings of Yan et al. Yan et al. teach the addition of dexamethasone to their culture media (Yan, paragraphs, 178 and 330) that grows bone marrow cells (Yan, paragraph 85) in a microgravity environment (Yan, paragraph 111) for bone marrow transplantation (Yan, paragraph 43) which is the same purpose as Goodwin et al. It would have been obvious to someone skilled in the art to add dexamethasone to the culture medium since Yan et al. and Goodwin #1 share the same purpose, see M.P.E.P. § 2144.06.

Furthermore both the addition of TGF-  $\beta$  and dexamethasone to the culture medium would be seen as obvious improvements to the known technique of Goodwin #1 since both improve the production of cartilage tissue in traditional culture methods (KSR International Co. v. Teleflex Inc., 550 U.S.--, 82 USPQ2d 1385 (2007)) .

Therefore, the invention as a whole would have been prima facie obvious at the time of filing in view of the references listed above and as such claims 1-5, 7 and 9 are not allowable.

No claims are currently allowed in this application.

**In response to this office action the applicant should specifically point out the support for any amendments made to the disclosure**, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP § 2163.06 for

interpreting claims, it is noted that other art may be applicable under 35 U.S.C. § 102 or 35 U.S.C. § 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is requested to provide a list of all copending U.S. applications that set forth similar subject matter to the present claims. A copy of such copending claims is requested in response to this Office action.

#### CONTACT INFORMATION

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thane Underdahl whose telephone number is (571) 272-9042. The examiner can normally be reached Monday through Thursday, 8:00 to 17:00 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached at (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Thane Underdahl  
Art Unit 1651

/Leon B Lankford/  
Primary Examiner, Art Unit 1651